| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
20,815 |
20,074 |
$5.93M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
23,335 |
22,583 |
$4.28M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
14,406 |
13,571 |
$727K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,453 |
3,298 |
$336K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,708 |
1,690 |
$214K |
| 80053 |
Comprehensive metabolic panel |
5,549 |
5,252 |
$199K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
18,270 |
17,221 |
$186K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
5,136 |
4,473 |
$180K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,342 |
2,076 |
$160K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
6,816 |
6,380 |
$133K |
| 71046 |
Radiologic examination, chest; 2 views |
1,640 |
1,561 |
$93K |
| 36415 |
Collection of venous blood by venipuncture |
14,469 |
12,726 |
$90K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
209 |
194 |
$86K |
| 85027 |
|
4,002 |
3,828 |
$71K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
799 |
722 |
$44K |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,225 |
849 |
$26K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
189 |
185 |
$23K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
330 |
315 |
$23K |
| 71045 |
Radiologic examination, chest; single view |
251 |
243 |
$20K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
342 |
319 |
$18K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
39 |
38 |
$17K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
753 |
738 |
$16K |
| D2930 |
Prefabricated stainless steel crown - primary tooth |
26 |
25 |
$14K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,243 |
644 |
$13K |
| 81001 |
|
1,006 |
961 |
$12K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
208 |
200 |
$11K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,422 |
2,246 |
$11K |
| D2393 |
Resin-based composite - three surfaces, posterior, primary or permanent |
12 |
12 |
$10K |
| 83690 |
|
1,285 |
1,239 |
$7K |
| 84484 |
|
1,232 |
965 |
$7K |
| D3220 |
Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction |
29 |
27 |
$7K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,516 |
1,439 |
$7K |
| 82248 |
|
1,277 |
1,224 |
$6K |
| J2704 |
Injection, propofol, 10 mg |
877 |
822 |
$6K |
| D7140 |
Extraction, erupted tooth or exposed root |
24 |
24 |
$6K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
466 |
436 |
$5K |
| 87081 |
|
379 |
359 |
$4K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
52 |
16 |
$4K |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
3,584 |
2,624 |
$3K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
40 |
39 |
$3K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
40 |
15 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
158 |
153 |
$3K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
89 |
53 |
$2K |
| 84703 |
|
201 |
191 |
$2K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
115 |
104 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
41 |
38 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
297 |
270 |
$1K |
| 84512 |
|
54 |
50 |
$873.66 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
233 |
224 |
$805.74 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
150 |
145 |
$679.65 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
13 |
13 |
$489.49 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
110 |
104 |
$455.72 |
| 84145 |
|
14 |
12 |
$436.51 |
| 83605 |
|
68 |
55 |
$401.24 |
| 81025 |
|
52 |
51 |
$385.90 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
38 |
37 |
$346.04 |
| 86803 |
|
13 |
13 |
$301.00 |
| 80061 |
Lipid panel |
13 |
13 |
$253.86 |
| 81003 |
|
46 |
40 |
$196.61 |
| 87807 |
|
12 |
12 |
$159.72 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
38 |
37 |
$158.58 |
| 86140 |
|
14 |
13 |
$124.35 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
76 |
74 |
$53.53 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
17 |
13 |
$45.25 |
| J2004 |
Injection, lidocaine hcl with epinephrine, 1 mg |
12 |
12 |
$0.00 |